Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) remains a clinical challenge due to antibiotic resistance. Its virulence factor, a-hemolysin, disrupts host membranes but is highly cytotoxic, requiring safer variants. This study uses an attenuated a-hemolysin mutant (H35/48L) as an antigen candidate. To enhance stability and immunogenicity, it was encapsulated in multilamellar lipid nanovesicles composed of DPPC, cholesterol, and Ecoceramide ENP. These vesicles ensure high antigen encapsulation and serum stability, providing a promising vaccine platform.
Learning Objectives:
Explore the MRSA infections, implications for patient morbidity and public healthcare.
